Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer

Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer

US Patent 10471160 · Granted Nov 12, 2019

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Prodrugs of 2-PMPA for healthy tissue protection during PSMA-targeted cancer ima2025
Double-labeled probe for molecular imaging and use thereof2024
Double-labeled probe for molecular imaging and use thereof2024
Double-labeled probe for molecular imaging and use thereof2024
18F-tagged inhibitors of prostate specific membrane antigen (PSMA) and their use2024
18F-tagged inhibitors of prostate specific membrane antigen (PSMA) and their use2024
18F-tagged inhibitors of prostate specific membrane antigen (PSMA) and their use2024
18F-tagged inhibitors of prostate specific membrane antigen (PSMA) and their use2024
18F-tagged inhibitors of prostate specific membrane antigen (PSMA) and their use2024
Use of labeled inhibitors of prostate specific membrane antigen (PSMA), as agent2024
Use of labeled inhibitors of prostate specific membrane antigen (PSMA), as agent2024
Use of labeled inhibitors of prostate specific membrane antigen (PSMA), as agent2024